LogicBio Therapeutics Inc

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases. Their proprietary technology based on the non-pathogenic adeno-associated viral vector offers superior efficiency and safety compared to all competitors on the market and is uniquely suited for the treatment of children as well as adults.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, Del.--( BUSINESS WIRE )--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction   LEXINGTON, Mass. , Nov. 14, 2022  /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended September 30, 2022 and provided business updates.

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating LogicBio Therapeutics, Inc. (LOGC), relating to its proposed acquisition by AstraZeneca Rare Disease. Under the terms of the tender offer, LOGC shareholders will receive $2.07 in cash per share they own.

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LogicBio Therapeutics, Inc. ("LogicBio" or the "Company") (NASDAQ: LOGC), in connection with the proposed acquisition of the Company by AstraZeneca Rare Disease ("Alexion") via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $2.07 in cash for each share of LogicBio common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.

MILWAUKEE , Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.  Click here to learn how to join the action: https://www.ademilaw.com/case/logicbior-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca

Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-stage genetic medicine company. The deal has Alexion agreeing to a cash tender offer for all outstanding shares of LOGC stock.

Why Is LogicBio (LOGC) Stock Up 600% Today?

AstraZeneca

Shares of LogicBio Therapeutics Inc. LOGC, +641.32% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's AZN, +0.09% AZN, -1.53% Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million

LogicBio's stock skyrockets after buyout bid for a 667% premium

LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details.

Why AstraZeneca (AZN) Is Buying LogicBio Therapeutics (LOGC) In About A $68 Million Deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders. Halper Sadeh encourages LogicBio shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Logi

LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.

AstraZeneca pays 660% premium for gene therapy firm LogicBio

WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion's growth in genomic medicines through LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development. "The proposed acquisition of LogicBio is a

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

Ashford Hospitality Trust

BankFinancial

Consolidated Water

ProPhase Labs

A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.

5 Big Winners as Dollar Strengthens on Fed Rate Hike

Douglas Emmett

Eastside Distilling

Seabridge Gold

Suzano S.A. - ADR

Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).

5 Winning Stocks Backed by the Overlooked Trick of Rising P/E

Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet. LEXINGTON, Mass.

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression - Two of four patients demonstrated increasing ALB-2A levels over time, indicating expansion of edited hepatocytes carrying the corrective gene - Proprietary manufacturing process, mAAVRx, has shown 15- to 30-fold yield increase over standard transfection processes LEXINGTON, Mass. , Aug. 15, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the second quarter ended June 30, 2022, and provided business updates, including early clinical data from its ongoing SUNRISE trial evaluating LB-001 in pediatric patients with severe methylmalonic acidemia (MMA).

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

LogicBio Therapeutics (LOGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade

LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C.

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

–FDA lifted  clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 –LogicBio to present at ASGCT 2022 Annual Meeting LEXINGTON, Mass. , May 16, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

- GeneRide ® LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers -Proprietary AAV transfection process, harnessing mAAVRx™ system, showed 15- to 30-fold yield increase over standard processes -Improved downstream process resulted in increased purity and potency, and substantially reduced manufacturing timeline, of LK03 capsid vector LEXINGTON, Mass. , May 11, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C.

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with.

Why LogicBio Therapeutics Shares Are Popping Off Today

Acer Therapeutics

RealNetworks

ServiceSource

Penny stocks to watch as stock market crash continues. The post Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides

The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients.  Methylmalonic acidemia is an.

LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial

–Company initiates activities to resume dosing –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LEXINGTON, Mass. , May 9, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company's LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia.

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ®  Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C.

News for LogicBio Therapeutics Inc Stock (LOGC)